Abstract:
본 발명은 불활화시킨 TGEV 및 PEDV를 항원으로 하는 혼합불활화 백신을 제공한다. 또한, 본 발명은 (1) TGEV를 ST세포에서 배양하고, PEDV를 Vero 세포에서 배양하는 단계; (2) 상기 단계 1의 배양액을 원심분리하여 고역가의 TGEV 및 PEDV (10 7.0 TCID 50 /ml 이상)를 함유한 상층액을 분리하는 단계; (3) 상기 단계 2에서 얻은 상층액에 바이러스 불활화제를 첨가하여 각 바이러스를 불활화시키는 단계; (4) 상기 불활화시킨 배양액을 ST 및 Vero 세포에 접종하여 세포변성유무를 확인하는 단계; 및 (5) 상기 불화화시킨 바이러스 배양액을 혼합하는 단계를 포함함을 특징으로 하는 혼합불활화 백신의 제조방법을 제공한다. 또한, 본 발명은 상기 본 발명에 따른 혼합불활화 백신을 돼지의 분만 5∼7주전 및 2∼3주전에 각각 2회 접종하여 모돈의 초유로부터 TGEV 및 PEDV 항체를 자돈에 전달하는 것을 특징으로 하는 돼지바이러스성 설사병의 예방방법을 제공한다. 상기 구성에 의하면, 주요 돼지 바이러스성 설사병의 원인체인 TGEV 및 PEDV를 충분히 예방하여 안전성이 우수하면서도 포유자돈에서의 설사병으로 인한 피해를 최소화하는 것이 가능해진다.
Abstract:
The present invention relates to an inactivated vaccine composition for Japanese encephalitis containing Japanese encephalitis virus KV1899 strain antigens inactivated by BEI (binaryethyleneimine) and swine GM-CSF recombinant protein. The Japanese encephalitis virus KV1899 strain antigens inactivated by BEI and the swine GM-CSF recombinant protein have excellent immunogenicity, are suitable for the production of a vaccine by being mass-produced in insect cells, and match the genotype of genotype 1 Japanese encephalitis virus to be used as an effective vaccine for Japanese encephalitis without the problems of an existing live vaccine for Japanese encephalitis.
Abstract:
PURPOSE: A method for preparing an antigen for hemagglutination of rabbit hemorrhagic disease variant virus and recombinant inactivated vaccine is provided to reduce biological risk. CONSTITUTION: An antigen for suppressing hemagglutination is prepared by inoculating recombinant baculovirus prepared from VP60 gene(deposit number: KCTC 11756BP) of rabbit hemorrhagic disease variant virus into tissue culture cells. The tissue cultured cell is an insect cell(sf-9cell). A method for manufacturing an recombinant inactivated vaccine comprises: a stepo f cloning VP60 genes into pGEM-T vector; a step of cloning to pBuleBacHis4.5 vector to prepare recombinant baculovirus; a step of inoculating the baculovirus into the insect cells to prepare VP gene recombinant protein; a step of isolating antigen from the recombinant protein; and a step of inactivating the antigen.
Abstract:
PURPOSE: A veterinary composition containing sulpyrine is provided to dramatically treat anorectic problem and to enhance antibody formation rate. CONSTITUTION: A veterinary composition contains sulpyrine, antihistamines, and caffeine as an active ingredient and is used by mixing with a vaccine. The antihistamines are chlorpheniramine, diphenhydramine, tripelenamine, promethazine, or their veterinarily acceptable salt thereof.
Abstract:
PURPOSE: A vector for expressing IgG Fc domain on cell surface is provided to easily produce a vaccine having excellent immunogenicity to virus relating to bovine diseases. CONSTITUTION: A vector for expressing bovine IgG Fc domain contains a gene encoding the IgG Fc domain and gene encoding transmembrane domain of bovine transferring receptor. The gene encoding the transmembrane domain of bovine transferring receptor comprises a sequence of sequence number 5. The gene encoding Fc domain is a gene encoding hinge, CH2 and CH3. A method for manufacturing the vaccine to bovine disease-relating virus comprises: a step of infecting bovine disease-relating virus to a host cell using the expression vector to proliferate the virus; and a step of manufacturing the live vaccine or inactivated vaccine. The virus is bovine viral diarrhea virus (BVDV), ephemeral fever virus (BEF), bovine corona virus (BCV), bovine rotavirus (BoRotaV), bovine rhi notracheitis virus (IBRV), foot-and-mouth disease virus (FMDV), bovine parainfluenza virus (PI-3), blue tongue virus (BTV), bovine leukemia virus (BLV), cattle respirator syncytia virus (BRSV), akabane virus (AKV) or Ibaraki virus (IBV).